FDA RMAT status puts Rznomics’ RNA editing platform under a brighter clinical spotlight
RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.
Can VeonGen Therapeutics validate VR-based endpoints as Stargardt trials move toward pivotal design
VG801 shows early vision gains in Stargardt disease. Find out what this means for gene therapy endpoints and regulatory pathways.
iRegene’s NouvNeu001 becomes first iPSC therapy with RMAT and Fast Track designations
Find out how iRegene’s iPSC-based Parkinson’s therapy NouvNeu001 became the first to earn both RMAT and Fast Track status from the FDA.